{"id":"NCT00713323","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study to Compare the Safety and Tolerability of Sativex速 in Patients With Neuropathic Pain.","officialTitle":"A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex速 in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2007-06","completion":"2007-06","firstPosted":"2008-07-11","resultsPosted":"2012-09-14","lastUpdate":"2023-05-03"},"enrollment":380,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Pain","Peripheral Neuropathy"],"interventions":[{"type":"DRUG","name":"Sativex速","otherNames":["GW-1000-02"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex速 in relieving neuropathic pain.","primaryOutcome":{"measure":"Change From Parent Study Baseline in Mean Pain 0-10 Numerical Rating Scale (NRS) Score During the Last 4 Weeks of Open-label Treatment","timeFrame":"38 weeks","effectByArm":[{"arm":"Sativex","deltaMin":-2.07,"sd":2.13}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":380},"commonTop":["Dizziness","Nausea","Fatigue","Dry Mouth","Dysgeusia"]}}